Darwin Biosciences
Darwin Biosciences is a Boulder, Colorado-based biotechnology company developing a self-contained, saliva-based point-of-care diagnostic platform that detects immune signatures of acute-phase infections using proprietary biomarkers and RNA amplification, targeting hospitals, military medical applications, and POC diagnostics licensees.
- Company typePrivate
- Founded2020
- HeadquartersBoulder, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Darwin Biosciences does
Darwin Biosciences is a Boulder, Colorado-based private biotechnology company founded in March 2020 that develops saliva-based point-of-care diagnostic devices for the early detection of infectious diseases. Its core technology is a self-contained diagnostic platform that uses a proprietary biomarker panel combined with on-board RNA amplification to detect immune signatures indicative of acute-phase infections, enabling identification of infections regardless of pathogen type. The device operates independently of laboratories and external power, supports non-invasive saliva sampling, and delivers results through a fully automated workflow spanning collection, processing, amplification, and results presentation. The technology originated from DTRA-funded military research for rapid field-deployable diagnostics, and Darwin's COVID-19 saliva test was validated and deployed thousands of times during the pandemic before the company refocused on sepsis detection as its primary clinical application.
The company's commercial strategy centers on enterprise field sales to hospitals and clinical settings, alongside a licensing and co-development channel targeting other point-of-care diagnostics companies in both human and animal health markets. Darwin identifies three primary customer segments: hospital and clinical settings (primary, focused on sepsis where each hour of delayed treatment increases mortality risk by 8%), military medical applications, and POC diagnostics firms seeking to license the underlying platform technology. Revenue mechanics span diagnostic device sales (hardware), technology licensing and royalties, and strategic co-development arrangements. As of available data, the company has raised $17 million in an undisclosed funding round, has 11-50 employees, and is actively seeking additional venture capital and strategic collaborators to advance commercialization.
Darwin is led by co-founders Nick Meyerson PhD (CEO, expertise in evolution, virology, and immunology) and Sara Sawyer PhD (Director, Professor at CU Boulder), with Amy Emerman PhD overseeing product development and Claire Alexander BSN/MBA leading clinical affairs and operations. Scientific and medical advisors include faculty from CU Boulder and Duke University, providing academic validation and clinical translation support. Core institutional partnerships span CU Boulder, Duke University, the Defense Threat Reduction Agency (DTRA), and UMU, reflecting the technology's military origins and dual-use positioning across defense and civilian healthcare markets.
Darwin Biosciences firmographics
Firmographics- Name
- Darwin Biosciences
- Legal name
- Darwin Biosciences
- Website
- https://darwin.bio
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Darwin Biosciences is a Boulder, Colorado-based biotechnology company developing a self-contained, saliva-based point-of-care diagnostic platform that detects immune signatures of acute-phase infections using proprietary biomarkers and RNA amplification, targeting hospitals, military medical applications, and POC diagnostics licensees.
- Ownership category
- akta.pro rank
Darwin Biosciences industry classification
Industry- Product category
- Point-of-Care Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
- akta.pro secondary industries
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
Keywords
Where Darwin Biosciences is headquartered
LocationHeadquarters
- HQ city
- Boulder
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Darwin Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Diagnostic Device Sales: Sale of point-of-care diagnostic devices for disease detection in clinical, military, and field settings.
- Technology Licensing: Licensing of platform technology to other companies developing POC molecular diagnostics in human and animal health markets.
- Strategic Partnership Development: Co-development and strategic collaboration arrangements with industry partners for specific disease applications.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels2 records
Darwin Biosciences product offering
Product offeringCore offering
Darwin Biosciences develops and sells a self-contained, point-of-care diagnostic device that uses a proprietary biomarker panel to detect immune signatures indicative of acute-phase infections from saliva samples. The platform integrates non-invasive sample collection, on-board RNA amplification, and automated results presentation without requiring laboratory infrastructure or external power. The company primarily targets sepsis detection in clinical settings and offers the technology as a licensing/co-development foundation for broader human and animal health diagnostics.
Product overview
Darwin Biosciences offers a single unified product: the Darwin Point-of-Care Diagnostic Platform. This self-contained device leverages a unique biomarker panel to detect immune signatures indicative of acute-phase infections through a fully automated workflow (saliva collection, processing, RNA amplification, and results presentation). The platform is designed for scalability across disease spaces including sepsis (primary focus), Ebola, and other infectious diseases. The company previously developed a COVID-19 saliva-based test that was validated and deployed at scale before evolving the technology into the current sepsis-focused platform. The platform serves as a foundation technology for strategic partnerships in human and animal health POC molecular diagnostics.
Differentiator
Problem solved
Functional benefit
Products and services
- Darwin Point-of-Care Diagnostic Platform A self-contained, field-deployable diagnostic device that uses a proprietary biomarker panel to detect immune signatures indicative of acute-phase infections. It performs non-invasive saliva collection, on-board RNA amplification, and automated results presentation without requiring laboratory infrastructure or external power, serving as a foundation for diagnostic applications across human and animal health.
- COVID-19 Saliva-Based Diagnostic Test A non-invasive saliva-based COVID-19 diagnostic test developed during Darwin's initial 2020 pivot that was proven comparable to other tests and used thousands of times, and from which the broader point-of-care diagnostic platform subsequently evolved.
Quantifiable outcome
- Every hour that a septic patient goes without treatment increases the risk of death by 8%
- +1 more outcomes
Companies that use Darwin Biosciences
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles4 records
Darwin Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
Darwin Biosciences partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and flagship.
- University of Colorado (CU Boulder)coreUniversity partnership providing scientific leadership through co-founder Sara Sawyer (Professor) and scientific advisor Daniel Larremore (Associate Professor). Core academic collaborator supporting technology development and validation.
- Duke UniversitycoreAcademic medical partnership providing medical expertise through advisor Micah McClain (Associate Professor). Supports clinical validation and medical advisory guidance.
- Defense Threat Reduction Agency (DTRA)flagshipOriginal technology development was funded through DTRA military research program aimed at developing rapid, field-deployable diagnostic solutions. Military roots of the platform technology.
- US GovernmentflagshipOriginal mission challenge from US Government to 'limit disease outbreaks with an easy-to-use device that detects the presence of all known and unknown pathogens' that inspired Darwin's founding and technology development.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
Darwin Biosciences competitors and assessment
Company assessmentBroad incumbents
- Cepheid (Danaher): Established leader in molecular point-of-care diagnostics with the GeneXpert system deployed across hospitals worldwide for infectious disease detection. Directly comparable to Darwin's POC molecular diagnostics ambition and sepsis-relevant menu, with a much larger installed base and FDA-cleared assays.
- BioFire Diagnostics (bioMérieux): Operates the FilmArray syndromic molecular diagnostic platform widely used in hospital settings for rapid pathogen identification including sepsis and bloodstream infections. Comparable as a hospital-focused molecular diagnostics incumbent and a natural channel competitor to Darwin's POC sepsis device.
- QuidelOrtho: Broad diagnostics incumbent offering Sofia and other rapid point-of-care immunoassay and molecular platforms for infectious disease detection. Comparable as an established POC infectious disease diagnostics player with hospital and clinical channels Darwin is targeting.
- Abbott Diagnostics: Major diagnostics incumbent operating the ID NOW molecular POC platform and Alinity suite used in hospital and clinical settings for rapid infectious disease detection. Comparable as a global POC molecular diagnostics incumbent with overlapping menu and channel focus.
Direct peers
- T2 Biosystems: Developer of T2 Magnetic Resonance-based direct-from-blood diagnostics for sepsis-causing pathogens and Candida species. Closely comparable as a sepsis-focused molecular diagnostics company pursuing rapid, non-culture-based detection in hospital settings.
- Accelerate Diagnostics: Developer of the Accelerate Pheno system for rapid identification and antimicrobial susceptibility testing direct from positive blood cultures in sepsis. Comparable as a rapid molecular diagnostics company focused on bloodstream infection and sepsis decision support in hospitals.
Emerging players
- Cytovale: Developer of the IntelliSep host-response cellular biomarker assay for early sepsis detection in emergency departments. Directly comparable as a host-response-based sepsis diagnostics company targeting rapid hospital triage, with overlapping clinical positioning to Darwin.
- Inflammatix: Developer of host-response diagnostics using blood-based mRNA signatures to rapidly distinguish bacterial vs viral infection and stratify sepsis risk. Comparable as a host-response / immune-signature diagnostics company focused on acute infection, with similar mechanistic underpinnings to Darwin's biomarker panel.
Regional players
- Mesa Labs: Provides diagnostics and quality control solutions including rapid microbial and molecular detection products serving clinical, pharmaceutical, and industrial markets. Comparable as a diagnostics company with adjacent rapid-detection products serving clinical and adjacent verticals.
Others
- Qiagen: Provider of molecular sample-prep, PCR/NGS assays, and QIAstat-Dx syndromic testing platforms widely used in hospital and research settings. Comparable as an enabling technology supplier in the molecular diagnostics ecosystem, with overlap on nucleic acid amplification and assay chemistry relevant to Darwin's platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Darwin Biosciences social profiles
Digital presenceDarwin Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Darwin Biosciences leadership team
Management profileNumber of profiles
Profiles8 records
Darwin Biosciences funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Darwin Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Darwin Biosciences
What does Darwin Biosciences do?
Darwin Biosciences develops and sells a self-contained, point-of-care diagnostic device that uses a proprietary biomarker panel to detect immune signatures indicative of acute-phase infections from saliva samples. The platform integrates non-invasive sample collection, on-board RNA amplification, and automated results presentation without requiring laboratory infrastructure or external power. The company primarily targets sepsis detection in clinical settings and offers the technology as a licensing/co-development foundation for broader human and animal health diagnostics.
Is Darwin Biosciences a public or private company?
Darwin Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Darwin Biosciences founded?
Darwin Biosciences was founded in 2020. It employs 11 to 50 people.
Where is Darwin Biosciences based?
Darwin Biosciences is headquartered in Boulder, United States, in the North America region.
How does Darwin Biosciences make money?
Three revenue lines are on record. Diagnostic Device Sales are the primary driver. The others are technology Licensing and strategic Partnership Development.
Who are Darwin Biosciences's main competitors?
Broad incumbents on record are Cepheid (Danaher), BioFire Diagnostics (bioMérieux), QuidelOrtho and Abbott Diagnostics. Direct peers are T2 Biosystems and Accelerate Diagnostics. Emerging players are Cytovale and Inflammatix. Mesa Labs is listed as a regional player. Qiagen is listed as an others.
Does Darwin Biosciences have an API?
No public API is recorded for Darwin Biosciences.
What industry is Darwin Biosciences in?
Darwin Biosciences's product category is Point-of-Care Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 325413 and its SIC code is 2835.